Legend Biotech Reports Q4 and Full-Year 2023 Financials with Focus on Carvykti Milestones
Legend Biotech Corporation (NASDAQ: LEGN) has released its financial results for the fourth quarter and...
Finanical Reports
Merck’s 2023 Annual Report: A Mixed Bag Amid Global Challenges
Merck KGaA (ETR: MRK), a leading German chemical, reported a 5.6% decline in its global...
Lundbeck A/S Posts 8.2% YOY Revenue Growth in 2023 with Strong Performance Across Key Therapies
Danish pharmaceutical company Lundbeck A/S (FRA: LDBB) has announced its financial results for 2023, highlighting...
Bayer Posts 1.2% YOY Sales Decline in 2023 with Pharmaceuticals and Consumer Health Segment Updates
Germany’s Bayer (ETR: BAYN) has released its financial results for 2023, marking a year of...
Henlius Biotech Forecasts First-Ever Profit in 2023 Driven by Sales Growth and Efficient Management
Shanghai Henlius Biotech Inc., (HKG: 2696), a China-based biopharmaceutical company, has released a positive profit...
MicroPort CardioFlow Forecasts 31%-36% YOY Sales Growth for 2023 Driven by TAVI Product Expansion
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG:...
HutchMed’s 2023 Financials Show 102% YOY Revenue Growth and Robust Collaboration with Takeda
HutchMed (HKG: 0013, NASDAQ: HCM), a China-based biopharmaceutical company, has released its financial report for...
Viatris Eyes Growth After Concluding Initial Phase of Strategy with 2023 Sales at $15.4 Billion
US generics giant Viatris (NASDAQ: VTRS) reported a 4% year-on-year decline in global sales to...
Zai Lab Ltd Reports 31% YOY Growth in Product Revenues and Strategic Pipeline Expansion
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, has released its financial...
BeiGene Reports Record Revenues and Rapid Growth in Q4 and Full Year 2023 with Continued Expansion
BeiGene (NASDAQ: BGNE), a China-based biopharmaceutical company, has presented its financial results for the fourth...
Organon Reports Q4 2023 Revenue Growth Driven by Women’s Health and Biosimilars
Organon (NYSE: OGN), the U.S.-based pharmaceutical company, has reported its fourth-quarter 2023 financial results, revealing...
AstraZeneca Reports 6% Revenue Growth in 2023, Driven by Oncology and Diabetes Drug Sales
AstraZeneca (AZ; NASDAQ: AZN), the UK-based multinational, reported its financial results for 2023 this week,...
Gilead’s 2023 Flat Sales Reflect Stagnation and COVID-19 Demand Decline
Gilead Sciences Inc. (NASDAQ: GILD) has reported a stagnant performance for the year 2023, with...
Astellas Pharma Inc. Reports 2.1% YOY Growth in Q1-Q3 Fiscal 2023 Revenues
Tokyo-based pharmaceutical company Astellas Pharma Inc., (TYO: 4503) has announced financial results for the first...
Gilead’s 2023 Stagnation Foresees Flat 2024 Sales as Veklury Revenues Dwindle
Gilead Sciences (NASDAQ: GILD) has reported a stagnant performance for 2023, with product sales remaining...
Amgen’s Q4 2023 Results Showcase 9% YOY Growth, 18 Drugs Hit Record Sales
Biopharmaceutical giant Amgen (NASDAQ: AMGN) has reported its financial results for Q4 2023, announcing annual...
Eli Lilly’s 2023 Revenue Soars on Metabolism Drugs, Anticipates Further Growth in 2024
Eli Lilly and Company (NYSE: LLY) reported a robust 2023 financial performance with a 20%...
Innovent Biologics Posts 65% YOY Growth in Q4 2023 with Over RMB 1.6 Billion in Sales
Chinese biopharmaceutical company Innovent Biologics Inc., (HKG: 1801) has reported impressive quarterly sales figures, announcing...
Astellas Pharma Inc. Reports 2.1% YOY Growth in Q1-Q3 Fiscal 2023 Revenues
Japanese pharmaceutical corporation Astellas Pharma Inc., (TYO: 4503) has announced its financial results for the...
Beckton Dickinson’s Q1 Results Affected by Volume-Based Procurement, Life Sciences Growth
US-based medical technology company Beckton Dickinson (BD; NYSE: BDX) has reported its financial results for...